Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Upper Respiratory Drugs: Decongestants01:27

Upper Respiratory Drugs: Decongestants

Decongestants are a class of medications used primarily to alleviate nasal congestion, a common symptom resulting from allergies, colds, sinusitis, and other upper respiratory tract infections. These drugs work by activating α-adrenergic receptors, constricting small blood vessels in the nasal membranes. This action results in the opening of clogged nasal passages, thereby facilitating sinus drainage and relieving congestion.
Most decongestants are readily available over-the-counter in various...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How to Evaluate MADness Concerning the Valvular Apparatus?

Echocardiography (Mount Kisco, N.Y.)·2025
See all related articles

Related Experiment Video

Updated: May 29, 2026

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

Decongestion in chronic heart failure.

Antohi Laura1,2, Mihaileanu Serban3

  • 1Intensive Cardiac Care Unit of the Institute for Cardiovascular Diseases "C.C.Iliescu", Bucharest, Romania.

JRSM Cardiovascular Disease
|May 28, 2026
PubMed
Summary

Loop diuretics are key for heart failure decongestion but lack mortality benefits. Evidence suggests using the lowest effective dose and considering withdrawal in stable patients to improve prognosis.

Keywords:
Heart failuredecongestiondiuretics

Related Experiment Videos

Last Updated: May 29, 2026

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Congestion is a primary driver of heart failure symptoms and poor outcomes.
  • Loop diuretics are the standard treatment for decongestion in heart failure.
  • Current evidence does not support mortality benefits from aggressive diuretic strategies.

Purpose of the Study:

  • To review the role and evidence surrounding loop diuretic use in heart failure management.
  • To evaluate the association between diuretic dosage and patient prognosis.
  • To explore strategies for decongestion and diuretic deprescribing in heart failure.

Main Methods:

  • Review of randomized trials and observational data on diuretic strategies in heart failure.
  • Analysis of mechanistic studies on neurohormonal activation post-diuretic administration.
  • Synthesis of evidence regarding diuretic resistance, renal vulnerability, and specific HF phenotypes.

Main Results:

  • Loop diuretics do not demonstrate mortality benefit, despite aiding decongestion.
  • Higher diuretic doses (e.g., >40 mg/day furosemide equivalent) are linked to worse prognosis.
  • Diuretic withdrawal/reduction in stable patients may lower renin activity but lacks proven clinical outcome benefit.

Conclusions:

  • Maintain euvolemia using the lowest effective loop diuretic dose.
  • Consider monitored diuretic deprescribing in select low-risk, stable heart failure patients.
  • Further research is needed for optimal decongestive strategies and diuretic management across the HF spectrum.